Biotech bomb of the year! Innocan fuels hope for breakthrough in Alzheimer's, epilepsy or MS?!
Is InnoCan Pharma* (WKN: A2PSPW) on the verge of groundbreaking news? - Actually, everything points to it! The market also realizes that this share could be on the verge of a massive revaluation, which in my eyes should even be accompanied by gains in the 3-digit percentage range! The tension rises and the price also...
Now, of course, one can speculate that the research results that InnoCan Pharma* (WKN: A2PSPW) will publish soon, as announced, will have to do with one of the diseases mentioned. If these are scientifically relevant, and they are likely to be (patent application?), then this could lead to a run on the stock, as has been seen in the past.
But I would also like to share with you an excerpt from the study that I think is very relevant:
"The inhalation route remains the most common route of administration for CBD. Peak concentrations occurred rapidly after aerosolization or vaporization of CBD (200-300 mg/day, for 3-18 weeks), reaching approximately 31% of a final bioavailability. Nevertheless, this route of administration requires special equipment, so several approaches focus on producing the most suitable and resistant form of drug delivery. On the other hand, scientific studies have shown that CBD (up to 600 mg) administered orally in oil-based capsules resulted in a bioavailability of about 6%. Due to its low water solubility, absorption of CBD from the gastrointestinal system is impaired, resulting in very low bioavailability."
Especially for diseases that occur in seizure-like episodes, such as epilepsy or multiple sclerosis, a constant level of CBD in the body would potentially be beneficial. This can apparently be ensured with the LPT method from InnoCan Pharma* (WKN: A2PSPW), developed in the laboratory of Prof. Barenholz. Since CBD can obviously also be administered in high doses without major side effects, in my eyes a constantly high CBD level in the body would have a positive effect on the clinical picture in certain diseases.
So far, this is all pure speculation, but InnoCan Pharma* (WKN: A2PSPW) should soon put the cards on the table and I actually expect, especially just for the reasons mentioned, with a groundbreaking news! So if I should be right with my assumptions, then shortly the price of InnoCan will certainly no longer be held!
news from: wallstreet-online